On 10 March 2020, the Board of Directors of Targovax ASA approved the Company’s financial statements for 2019, which will be processed at the Company’s annual general meeting on 29 April 2020. The Company’s annual accounts for the financial year 2019, including the financial statements and annual report for the financial year 2019, are together with the auditor’s report attached to this notice. The documents are also available at the Company’s website, www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.